Filing Flows › 8-K events › Phathom Pharmaceuticals
Phathom Pharmaceuticals: other events
Form 8-K filed Oct 23, 2026 · items 8.01
What the filing says
On October 23, 2026, Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) announced that BDR Pharmaceuticals International Pvt. Ltd. (“BDR”) has filed suit against the U.S.
Read the filing on SEC EDGAR →
What usually followsAcross 44,881 8-Ks reporting Item 8.01 (other events) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.1%. Every item ranked →
Phathom Pharmaceuticals at a glance
Phathom Pharmaceuticals, Q3 2026: revenue $84.7M (+71% year over year), operating margin -0.1%. The chart follows the revenue to costs, profit and cash.
Phathom Pharmaceuticals: every quarter, Q/Q and Y/Y, holders and guidance →
Phathom Pharmaceuticals’s other material 8-Ks
Other recent fda decisions
- Biovie Nov 6, 2026
- Acrivon Therapeutics Nov 6, 2026
- Entera Bio Nov 6, 2026
- Precision Biosciences Nov 5, 2026
- Sintx Technologies Nov 5, 2026
- Microbot Medical Nov 5, 2026
- Bioxytran Nov 5, 2026
- Palvella Therapeutics Nov 5, 2026
- ANI Pharmaceuticals Nov 5, 2026
- Teleflex Nov 5, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.